Activity Overview
This online, on-demand virtual symposium brings together renowned experts in non–small cell lung cancer (NSCLC). In this educational program, these experts use realistic cases to explore key decision points in applying HER2- and TROP2-targeted therapies across the NSCLC continuum, including patient selection, therapeutic sequencing, and toxicity management.
This educational activity is an archive of the live symposium held on February 19, 2026.
Target Audience
This educational activity is directed toward medical and thoracic oncologists, pulmonologists, pathologists, nurses, nurse practitioners, physician assistants, pharmacists, and other health care practitioners involved in the management of NSCLC.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Determine the clinical importance of distinguishing between HER2 mutations, amplifications, and HER2 protein overexpression in managing advanced NSCLC
- Integrate current data supporting HER2-directed therapies to develop personalized treatment plans for patients with advanced NSCLC harboring HER2 alterations
- Examine the role of TROP2-targeted ADCs in advanced NSCLC with and without targetable genomic alterations
- Implement evidence-based strategies to prevent and manage adverse events linked to HER2- and TROP2-directed therapies in NSCLC
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here